Login to Your Account

Neuralstem’s $19.6M offering takes ALS bid through phase II

By Randy Osborne
Staff Writer

Friday, January 3, 2014
Neuralstem Inc.’s $19.65 million from a stock offering will help advance the lead compound NSI-566 in amyotrophic lateral sclerosis (ALS), which is “about halfway through” a Phase II trial, said CEO Richard Garr.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription